FDA Grants Breakthrough Therapy Designation to Device to Treat AML-Induced Depression

01/10/2022

Article Excerpt: The FDA has granted a breakthrough device designation to BNT200, a digital therapeutic designed to treat anxiety and depressive symptoms in adults with acute myeloid leukemia (AML) currently hospitalized for a regimen of high-intensity induction chemotherapy, according to a press release by Blue Note Therapeutics. BNT200 is a software that is designed to treat the unique psychological stressors that create anxiety and depressive symptoms in adult patients with AML undergoing high-intensity induction chemotherapy. It is an on-demand digital therapeutic, with content synchronized with high-intensity chemotherapy treatment.

Full Article: https://tinyurl.com/2p8pvxty

Article Source: Targeted Oncology